Sensory symptoms in restless legs syndrome: The enigma of pain

Sleep Medicine

Volumn 14, Issue 10, 2013, Pages 934-942

  Winkelman, John W ^a   Gagnon, Alison ^b   Clair, Andrew G ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UBC Scientific Solutions   (United States)

^c PFIZER INC   (United States)

Author keywords

Gabapentin; Neuropathy; Pain; Periodic leg movements; Pruritis; Restless legs syndrome; Sleep disorders

Indexed keywords

ANALGESIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; ANALGESIA; CAUSALGIA; CHRONIC DISEASE; CHRONIC PAIN; CIRCADIAN RHYTHM; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LEG MOVEMENT; LEG PAIN; MECHANORECEPTOR; MOTOR DYSFUNCTION; NERVE STIMULATION; NERVE TRACT; NEUROANATOMY; NEUROBIOLOGY; NEUROPATHIC PAIN; NOCICEPTION; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PHENOMENOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REST; RESTLESS LEGS SYNDROME; REVIEW; SENSORY DYSFUNCTION; SENSORY RECEPTOR; SENSORY STIMULATION; SIGNAL TRANSDUCTION; SLEEP DISORDER; SOMATOSENSORY SYSTEM;

GABAPENTIN; NEUROPATHY; PAIN; PERIODIC LEG MOVEMENTS; PRURITIS; RESTLESS LEGS SYNDROME; SLEEP DISORDERS;

AMINES; ANALGESICS; CHRONIC PAIN; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RESTLESS LEGS SYNDROME; SLEEP DISORDERS;

EID: 84883780132     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2013.05.017     Document Type: Review

References (115)

1. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
2. Winkelman J.W., Redline S., Baldwin C.M., Resnick H.E., Newman A.B., Gottlieb D.J. Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study. Sleep 2009, 32:772-778.
3. Fulda S., Wetter T.C. Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs 2005, 10:537-552.
4. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
5. Wesstrom J., Nilsson S., Sundstrom-Poromaa I., Ulfberg J. Restless legs syndrome among women: prevalence, co-morbidity and possible relationship to menopause. Climacteric 2008, 11:422-428.
6. Merskey H., Bogduk N. Part III: pain terms, a current list with definitions and notes on usage. Classification of chronic pain IASP task force on taxonomy 1994, IASP Press, Seattle (WA). 2nd ed.
7. Cross S.A. Pathophysiology of pain. Mayo Clin Proc 1994, 69:375-383.
8. Takeuchi Y., Takasu K., Ono H., Tanabe M. Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology 2007, 53:842-853.
9. Schaible H.G. Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol 2007, 3-28.
10. Latremoliere A., Woolf C.J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009, 10:895-926.
11. Karroum E.G., Golmard J.L., Leu-Semenescu S., Arnulf I. Sensations in restless legs syndrome. Sleep Med 2012, 13:402-408.
12. Tyvaert L., Laureau E., Hurtevent J.P., Hurtevent J.F., Derambure P., Monaca C. A-delta and C-fibres function in primary restless legs syndrome. Neurophysiol Clin 2009, 39:267-274.
13. Winkelmann J., Wetter T.C., Collado-Seidel V., Gasser T., Dichgans M., Yassouridis A., et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000, 23:597-602.
14. Hening W., Walters A.S., Allen R.P., Montplaisir J., Myers A., Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004, 5:237-246.
15. Bassetti C.L., Mauerhofer D., Gugger M., Mathis J., Hess C.W. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001, 45:67-74.
16. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975, 1:277-299.
17. Bentley A.J., Rosman K.D., Mitchell D. Can the sensory symptoms of restless legs syndrome be assessed using a qualitative pain questionnaire?. Clin J Pain 2007, 23:62-66.
18. Kushida C.A., Becker P.M., Ellenbogen A.L., Canafax D.M., Barrett R.W. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009, 72:439-446.
19. Cruccu G., Anand P., Attal N., Garcia-Larrea L., Haanpaa M., Jorum E., et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004, 11:153-162.
20. Wilkie D.J., Huang H.Y., Reilly N., Cain K.C. Nociceptive and neuropathic pain in patients with lung cancer: a comparison of pain quality descriptors. J Pain Symptom Manage 2001, 22:899-910.
21. Kerr S., McKinon W., Bentley A. Descriptors of restless legs syndrome sensations. Sleep Med 2012, 13:409-413.
22. Kushida C., Martin M., Nikam P., Blaisdell B., Wallenstein G., Ferini-Strambi L., et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007, 16:617-624.
23. Pelletier G., Lorrain D., Montplaisir J. Sensory and motor components of the restless legs syndrome. Neurology 1992, 42:1663-1666.
24. Birinyi P.V., Allen R.P., Lesage S., Dean T., Earley C.J. Investigation into the correlation between sensation and leg movement in restless legs syndrome. Mov Disord 2005, 20:1097-1103.
25. Trenkwalder C., Bucher S.F., Oertel W.H. Electrophysiological pattern of involuntary limb movements in the restless legs syndrome. Muscle Nerve 1996, 19:155-162.
26. Chen P.K., Fuh J.L., Chen S.P., Wang S.J. Association between restless legs syndrome and migraine. J Neurol Neurosurg Psychiatry 2010, 81:524-528.
27. Young W.B., Piovesan E.J., Biglan K.M. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr 2003, 8:450-456.
28. Yunus M.B., Aldag J.C. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996, 312:1339.
29. Salih A.M., Gray R.E., Mills K.R., Webley M. A clinical, serological and neurophysiological study of restless legs syndrome in rheumatoid arthritis. Br J Rheumatol 1994, 33:60-63.
30. Zoppi M., Maresca M. Symptoms accompanying fibromyalgia. Reumatismo 2008, 60:217-220.
31. Shaver J.L., Wilbur J., Robinson F.P., Wang E., Buntin M.S. Women's health issues with fibromyalgia syndrome. J Womens Health (Larchmt) 2006, 15:1035-1045.
32. Gemignani F., Marbini A., Di Giovanni G., Salih S., Margarito F.P., Pavesi G., et al. Cryoglobulinaemic neuropathy manifesting with restless legs syndrome. J Neurol Sci 1997, 152:218-223.
33. Gemignani F., Marbini A., Di Giovanni G., Salih S., Terzano M.G. Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Neurology 1999, 52:1064-1066.
34. Aigner M., Prause W., Freidl M., Weiss M., Izadi S., Bach M., et al. High prevalence of restless legs syndrome in somatoform pain disorder. Eur Arch Psychiatry Clin Neurosci 2007, 257:54-57.
35. Lopes L.A., Lins Cde M., Adeodato V.G., Quental D.P., de Bruin P.F., Montenegro R.M., et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care 2005, 28:2633-2636.
36. Gemignani F., Brindani F., Vitetta F., Marbini A. Restless legs syndrome and painful neuropathy-retrospective study. A role for nociceptive deafferentation?. Pain Med 2009, 10:1481-1486.
37. Gemignani F., Brindani F., Vitetta F., Marbini A., Calzetti S. Restless legs syndrome in diabetic neuropathy: a frequent manifestation of small fiber neuropathy. J Peripher Nerv Syst 2007, 12:50-53.
38. Hattan E., Chalk C., Postuma R.B. Is there a higher risk of restless legs syndrome in peripheral neuropathy?. Neurology 2009, 72:955-960.
39. Pourfar M., Feigin A. The numb and the restless: peripheral neuropathy and RLS. Neurology 2009, 72:950-951.
40. Cirignotta F., Mondini S., Santoro A., Ferrari G., Gerardi R., Buzzi G. Reliability of a questionnaire screening restless legs syndrome in patients on chronic dialysis. Am J Kidney Dis 2002, 40:302-306.
41. Benes H., Walters A.S., Allen R.P., Hening W.A., Kohnen R. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 2007, 22(Suppl. 18):S401-S408.
42. Gemignani F., Vitetta F., Brindani F., Contini M., Negrotti A. Painful polyneuropathy associated with restless legs syndrome. Clinical features and sensory profile. Sleep Med 2013, 14:79-84.
43. Kwak C., Dat Vuong K., Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord 2003, 18:1530-1533.
44. Himle M.B., Woods D.W., Conelea C.A., Bauer C.C., Rice K.A. Investigating the effects of tic suppression on premonitory urge ratings in children and adolescents with Tourette's syndrome. Behav Res Ther 2007, 45:2964-2976.
45. Michaud M., Lavigne G., Desautels A., Poirier G., Montplaisir J. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov Disord 2002, 17:112-115.
46. Cohen A.J., Leckman J.F. Sensory phenomena associated with Gilles de la Tourette's syndrome. J Clin Psychiatry 1992, 53:319-323.
47. Lesperance P., Djerroud N., Diaz Anzaldua A., Rouleau G.A., Chouinard S., Richer F. Restless legs in Tourette syndrome. Mov Disord 2004, 19:1084-1087.
48. Riviere J.B., Xiong L., Levchenko A., St-Onge J., Gaspar C., Dion Y., et al. Association of intronic variants of the BTBD9 gene with Tourette syndrome. Arch Neurol 2009, 66:1267-1272.
49. Stefansson H., Rye D.B., Hicks A., Petursson H., Ingason A., Thorgeirsson T.E., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007, 357:639-647.
50. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011, 20:173-196.
51. Scholz H., Trenkwalder C., Kohnen R., Riemann D., Kriston L., Hornyak M. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011, 3:CD006009.
52. Glynn C.J., Lloyd J.W. The diurnal variation in perception of pain. Proc R Soc Med 1976, 69:369-372.
53. Odrcich M., Bailey J.M., Cahill C.M., Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 2006, 120:207-212.
54. Giummarra M.J., Bradshaw J.L. The phantom of the night: restless legs syndrome in amputees. Med Hypotheses 2010, 74:968-972.
55. Galer B.S., Gianas A., Jensen M.P. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
56. Hening W.A., Walters A.S., Wagner M., Rosen R., Chen V., Kim S., et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 1999, 22:901-912.
57. Trenkwalder C., Hening W.A., Walters A.S., Campbell S.S., Rahman K., Chokroverty S. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord 1999, 14:102-110.
58. Rottach K.G., Schaner B.M., Kirch M.H., Zivotofsky A.Z., Teufel L.M., Gallwitz T., et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008, 43:70-75.
59. Patel T., Ishiuji Y., Yosipovitch G. Nocturnal itch: why do we itch at night?. Acta Derm Venereol 2007, 87:295-298.
60. Davidson S., Giesler G.J. The multiple pathways for itch and their interactions with pain. Trends Neurosci 2010, 33:550-558.
61. Vierow V., Fukuoka M., Ikoma A., Dorfler A., Handwerker H.O., Forster C. Cerebral representation of the relief of itch by scratching. J Neurophysiol 2009, 102:3216-3224.
62. Stiasny-Kolster K., Magerl W., Oertel W.H., Moller J.C., Treede R.D. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 2004, 127:773-782.
63. Bachmann C.G., Rolke R., Scheidt U., Stadelmann C., Sommer M., Pavlakovic G., et al. Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome. Brain 2010, 133:762-770.
64. Schattschneider J., Bode A., Wasner G., Binder A., Deuschl G., Baron R. Idiopathic restless legs syndrome: abnormalities in central somatosensory processing. J Neurol 2004, 251:977-982.
65. Lim Y.M., Chang S.E., Chung S., Kang B.H., Kim K.K. Small fiber function in drug naive patients with idiopathic restless legs syndrome. J Clin Neurosci 2012, 19:702-705.
66. Polydefkis M., Allen R.P., Hauer P., Earley C.J., Griffin J.W., McArthur J.C. Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology 2000, 55:1115-1121.
67. Bara-Jimenez W., Aksu M., Graham B., Sato S., Hallett M. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 2000, 54:1609-1616.
68. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006, 2:95-106.
69. Ziegler E.A., Magerl W., Meyer R.A., Treede R.D. Secondary hyperalgesia to punctate mechanical stimuli. Central sensitization to A-fibre nociceptor input. Brain 1999, 122(Pt. 12):2245-2257.
70. Manconi M., Ferri R., Zucconi M., Bassetti C.L., Fulda S., Arico D., et al. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol 2012, 71:834-844.
71. von Spiczak S., Whone A.L., Hammers A., Asselin M.C., Turkheimer F., Tings T., et al. The role of opioids in restless legs syndrome: an [11C] diprenorphine PET study. Brain 2005, 128:906-917.
72. Walters A.S., Ondo W.G., Zhu W., Le W. Does the endogenous opiate system play a role in the restless legs syndrome? A pilot post-mortem study. J Neurol Sci 2009, 279:62-65.
73. Unrath A., Juengling F.D., Schork M., Kassubek J. Cortical grey matter alterations in idiopathic restless legs syndrome: an optimized voxel-based morphometry study. Mov Disord 2007, 22:1751-1756.
74. Unrath A., Muller H.P., Ludolph A.C., Riecker A., Kassubek J. Cerebral white matter alterations in idiopathic restless legs syndrome, as measured by diffusion tensor imaging. Mov Disord 2008, 23:1250-1255.
75. Etgen T., Draganski B., Ilg C., Schroder M., Geisler P., Hajak G., et al. Bilateral thalamic gray matter changes in patients with restless legs syndrome. Neuroimage 2005, 24:1242-1247.
76. Celle S., Roche F., Peyron R., Faillenot I., Laurent B., Pichot V., et al. Lack of specific gray matter alterations in restless legs syndrome in elderly subjects. J Neurol 2010, 257:344-348.
77. Hornyak M., Ahrendts J.C., Spiegelhalder K., Riemann D., Voderholzer U., Feige B., et al. Voxel-based morphometry in unmedicated patients with restless legs syndrome. Sleep Med 2007, 9:22-26.
78. Vignatelli L., Billiard M., Clarenbach P., Garcia-Borreguero D., Kaynak D., Liesiene V., et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006, 13:1049-1065.
79. Chesson A.L., Wise M., Davila D., Johnson S., Littner M., Anderson W.M., et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999, 22:961-968.
80. Clemens S., Rye D., Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006, 67:125-130.
81. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008, 8:781-797.
82. Walters A.S., Wagner M.L., Hening W.A., Grasing K., Mills R., Chokroverty S., et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993, 16:327-332.
83. Ondo W.G. Methadone for refractory restless legs syndrome. Mov Disord 2005, 20:345-348.
84. Lauerma H., Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999, 60:241-244.
85. Kapur N., Friedman R. Oral ketamine: a promising treatment for restless legs syndrome. Anesth Analg 2002, 94:1558-1559. [table of contents].
86. Garcia-Borreguero D., Larrosa O., de la Llave Y., Verger K., Masramon X., Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002, 59:1573-1579.
87. Micozkadioglu H., Ozdemir F.N., Kut A., Sezer S., Saatci U., Haberal M. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open-label study. Ren Fail 2004, 26:393-397.
88. Kushida C.A., Walters A.S., Becker P., Thein S.G., Perkins A.T., Roth T., et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009, 32:159-168.
89. Sivam S., Yee B.J. Role of gabapentin enacarbil XR in restless legs syndrome. Ther Clin Risk Manag 2012, 8:201-208.
90. Walters A.S., Ondo W.G., Kushida C.A., Becker P.M., Ellenbogen A.L., Canafax D.M., et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009, 32:311-320.
91. Allen R., Chen C., Soaita A., Wohlberg C., Knapp L., Peterson B.T., et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010, 11:512-519.
92. Garcia-Borreguero D., Larrosa O., Williams A.M., Albares J., Pascual M., Palacios J.C., et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010, 74:1897-1904.
93. Sommer M., Bachmann C.G., Liebetanz K.M., Schindehutte J., Tings T., Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007, 115:347-350.
94. Dougherty P.M., Staats P.S. Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology 1999, 91:1891-1918.
95. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001, 81:299-343.
96. Dickenson A.H., Chapman V., Green G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol 1997, 28:633-638.
97. Bennett G.J. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000, 19:S2-S6.
98. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 2002, 7:837-844.
99. Sotgiu M.L., Valente M., Storchi R., Caramenti G., Biella G.E. Cooperative N-methyl-d-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res 2009, 60:284-290.
100. 2δ ligand pregabalin. J Neurosci 2009, 29:4076-4088.
101. 2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007, 28:75-82.
102. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007, 73:137-150.
103. Thorpe A.J., Offord J. The alpha2-delta protein: an auxiliary subunit of voltage-dependent calcium channels as a recognized drug target. Curr Opin Investig Drugs 2010, 11:761-770.
104. Tanabe M., Takasu K., Kasuya N., Shimizu S., Honda M., Ono H. Role of descending noradrenergic system and spinal α2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol 2005, 144:703-714.
105. Rahman W., Bauer C.S., Bannister K., Vonsy J.L., Dolphin A.C., Dickenson A.H. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol Pain 2009, 5:45.
106. Walters A., Hening W., Cote L., Fahn S. Dominantly inherited restless legs with myoclonus and periodic movements of sleep: a syndrome related to the endogenous opiates?. Adv Neurol 1986, 43:309-319.
107. Montplaisir J., Lorrain D., Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 1991, 31:41-43.
108. Walters A.S. Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med 2002, 3:301-304.
109. Barriere G., Cazalets J.R., Bioulac B., Tison F., Ghorayeb I. The restless legs syndrome. Prog Neurobiol 2005, 77:139-165.
110. Thorpy M.J., Diagnostic Classification Steering Committee International classification of sleep disorders, revised: diagnostic and coding manual 2001, American Academy of Sleep Medicine, Chicago (IL). 3rd ed.
111. Gibb W.R., Lees A.J. The restless legs syndrome. Postgrad Med J 1986, 62:329-333.
112. Stehlik R., Arvidsson L., Ulfberg J. Restless legs syndrome is common among female patients with fibromyalgia. Eur Neurol 2009, 61:107-111.
113. Mold J.W., Vesely S.K., Keyl B.A., Schenk J.B., Roberts M. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract 2004, 17:309-318.
114. Nineb A., Rosso C., Dumurgier J., Nordine T., Lefaucheur J.P., Creange A. Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. Eur J Neurol 2007, 14:788-792.
115. American Sleep Disorder Association International classification of sleep disorders, revised: diagnostic and coding manual 1997, Rochester, (MN).